|
SARS
|
2003
|
First isolation of the virus; sequencing of the entire virus genome; development of rapid diagnosis assays; establishment of SARS-designated hospitals and treatment of the patients
|
|
H5N1 avian flu
|
2004 to 2005
|
Large-scale industrial development of the Tamiflu equivalent, Oseltamivir (brand name KeWei)
|
|
H1N1 flu
|
2009
|
Confirmation of first input H1N1 infected case; development of rapid diagnosis assays and RT-PCR; development of Peramivir Trihydrate and H1N1 flu vaccine
|
|
H7N9 flu
|
2013 to 2016
|
Development of rapid diagnosis assays and RT-PCR; development of Peramivir and sodium chloride injection
|
|
Ebola hemorrhagic fever
|
2014 to 2015
|
Deployment of testing teams and mobile hospitals; treatment of patients and training of the health care workers; establishment and operation of biosafety III laboratory; development of Ebola drug MIL 77 and vaccine
|
|
Zika virus infection
|
2015 to 2016
|
Confirmation of first input Zika virus infection case; isolation of Zika virus strains; gene sequencing of the first imported Zika virus; development of rapid diagnosis assays
|
